MedTrace Logo

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

NCT00975650 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2018-08-13

Study results available
· View outcomes & findings →

Summary

This clinical trial is being performed to compare the pharmacokinetic profile of testosterone after repeated intra-nasal administration of products of different strengths in subjects with hypogonadism.

Conditions

  • Hypogonadism

Interventions

DRUG

Nasobol®

Intra-nasal Testosterone (2 syringes), b.i.d.

DRUG

Androderm® (Positive Control)

QD administration

Sponsors & Collaborators

  • Acerus Pharmaceuticals Corporation

    lead INDUSTRY

Principal Investigators

  • Paul Desjardins, Ph.D · Trimel Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00975650 on ClinicalTrials.gov